Trial Profile
Ipilimumab and Gemcitabine for Advanced Pancreas Cancer: A Phase Ib Study.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 24 Feb 2020 Status changed from active, no longer recruiting to completed.
- 07 Jun 2016 Results (n=16) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 21 Mar 2016 Planned number of patients changed from 28 to 21, according to ClinicalTrials.gov record.